Moreover, lymph node metastasis was detected in addition to the local recurrence in 18.6% of the patients by PSMA PET/CT, which subsequently led to an adjustment of the target volumes to cover all sites of visible disease with dose-escalated simultaneous integrated boost radiotherapy. The gene discussed is FOLH1; the disease is metastatic malignant neoplasm in the lymph nodes.